• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴基斯坦人群中脂蛋白(a)检测的频率及其水平

Frequency of lipoprotein(a) testing and its levels in Pakistani population.

作者信息

Batool Hijab, Khan Madeeha, Ain Quratul, Chughtai Omar R, Khan Muhammad D, Khan Mohammad I, Sadiq Fouzia

机构信息

Chemical Pathology, Chughtai Institute of Pathology, Lahore, Pakistan.

Directorate of Research, Shifa Tameer-e-Millat University, Pitras Bukhari Road, H-8/4, Islamabad 44000, Pakistan.

出版信息

Glob Cardiol Sci Pract. 2024 Aug 1;2024(4):e202437. doi: 10.21542/gcsp.2024.37.

DOI:10.21542/gcsp.2024.37
PMID:39351483
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11439424/
Abstract

BACKGROUND

Lipoprotein(a) [Lp(a)] is a highly atherogenic particle identified as an independent risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). This study aimed to investigate the frequency of Lp(a) testing and the incidence of elevated Lp(a) levels in the Pakistani population.

METHODS

For this observational study, Lp(a) and lipid profile data from five years (June 2015 to October 2020) were acquired from the electronic patient records of a diagnostic laboratory with a countrywide network. The association of age and total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL, and triglyceride (TG) levels with two thresholds for Lp(a), that is, <30 mg/dL and ≥30 mg/dL, was calculated using the Kruskal-Wallis test, while the association between Lp(a) levels and lipid variables was calculated using Spearman correlation.

RESULTS

For five years, 1060 tests were conducted, averaging 212 tests per year. Of these, 37.2% showed Lp(a) levels above 30 mg/dL. No significant differences were observed in the results between males and females. However, younger individuals displayed significantly higher Lp(a) levels. Additionally, there was only a weak correlation between the Lp(a) levels and other lipid variables.

CONCLUSION

Despite being recognized as a risk factor for ASCVD in the Pakistani population, only a small proportion of the large population underwent Lp(a) testing. Moreover, a significant proportion of the population exceeded this threshold.

摘要

背景

脂蛋白(a) [Lp(a)]是一种高度致动脉粥样硬化的颗粒,被确定为动脉粥样硬化性心血管疾病(ASCVD)发生的独立危险因素。本研究旨在调查巴基斯坦人群中Lp(a)检测的频率以及Lp(a)水平升高的发生率。

方法

在这项观察性研究中,从一个拥有全国性网络的诊断实验室的电子病历中获取了五年(2015年6月至2020年10月)的Lp(a)和血脂谱数据。使用Kruskal-Wallis检验计算年龄与总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、非HDL和甘油三酯(TG)水平与Lp(a)的两个阈值(即<30mg/dL和≥30mg/dL)之间的关联,而使用Spearman相关性计算Lp(a)水平与血脂变量之间的关联。

结果

在五年期间,共进行了1060次检测,平均每年212次。其中,37.2%的检测显示Lp(a)水平高于30mg/dL。男性和女性之间的结果未观察到显著差异。然而,较年轻的个体显示出显著更高的Lp(a)水平。此外,Lp(a)水平与其他血脂变量之间仅存在微弱的相关性。

结论

尽管Lp(a)在巴基斯坦人群中被公认为ASCVD的危险因素,但在大量人群中只有一小部分进行了Lp(a)检测。此外,相当一部分人群超过了这个阈值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/b07aa9c699dd/gcsp-2024-4-e202437-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/49702906901a/gcsp-2024-4-e202437-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/c5b58c39063a/gcsp-2024-4-e202437-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/7cce86a58d7b/gcsp-2024-4-e202437-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/b07aa9c699dd/gcsp-2024-4-e202437-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/49702906901a/gcsp-2024-4-e202437-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/c5b58c39063a/gcsp-2024-4-e202437-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/7cce86a58d7b/gcsp-2024-4-e202437-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c710/11439424/b07aa9c699dd/gcsp-2024-4-e202437-g004.jpg

相似文献

1
Frequency of lipoprotein(a) testing and its levels in Pakistani population.巴基斯坦人群中脂蛋白(a)检测的频率及其水平
Glob Cardiol Sci Pract. 2024 Aug 1;2024(4):e202437. doi: 10.21542/gcsp.2024.37.
2
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.降低“极高”ASCVD 风险患者的靶向致动脉粥样硬化脂蛋白胆固醇目标。
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.
3
Utility of Advanced Lipoprotein Testing in Clinical Practice先进脂蛋白检测在临床实践中的应用价值
4
Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects.脂蛋白(a)与 LDL 胆固醇水平在貌似健康人群心血管风险评估中的不相符性。
Nutr Metab Cardiovasc Dis. 2023 Jul;33(7):1429-1436. doi: 10.1016/j.numecd.2023.04.010. Epub 2023 Apr 14.
5
Assessment of Lipoprotein (a) Levels in Patients with Atherosclerotic Cardiovascular Disease: Single Center Experience from Türkiye.载脂蛋白(a)水平在动脉粥样硬化性心血管疾病患者中的评估:来自土耳其的单中心经验。
Turk Kardiyol Dern Ars. 2024 Sep;52(6):384-389. doi: 10.5543/tkda.2024.70979.
6
Serum apolipoprotein B/apolipoprotein A1 ratio in relation to intervertebral disk herniation: a cross-sectional frequency-matched case-control study.血清载脂蛋白 B/载脂蛋白 A1 比值与椎间盘突出症的关系:一项横断面频数匹配的病例对照研究。
Lipids Health Dis. 2021 Jul 29;20(1):79. doi: 10.1186/s12944-021-01502-z.
7
Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan.日本血清脂蛋白(a)水平及其与动脉粥样硬化性心血管疾病的关联。
J Atheroscler Thromb. 2025 Apr 1;32(4):421-438. doi: 10.5551/jat.64953. Epub 2024 Oct 5.
8
In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.在儿科家族性高胆固醇血症中,脂蛋白(a)比 LDL-C 更能预测家族成员心血管疾病的早发。
J Clin Lipidol. 2018 Nov-Dec;12(6):1445-1451. doi: 10.1016/j.jacl.2018.07.014. Epub 2018 Jul 31.
9
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.脂质测量在心血管疾病管理中的应用:实用建议——国家脂质协会写作组的科学声明。
J Clin Lipidol. 2021 Sep-Oct;15(5):629-648. doi: 10.1016/j.jacl.2021.09.046. Epub 2021 Sep 24.
10
Low-density lipoprotein apheresis: an evidence-based analysis.低密度脂蛋白单采术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

本文引用的文献

1
Lipoprotein(a): from Causality to Treatment.脂蛋白(a):从因果关系到治疗。
Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22.
2
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.雷帕霉素靶向载脂蛋白(a)的长持续时间短干扰 RNA(Lepodisiran):一项随机剂量递增临床试验。
JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835.
3
Mapping of familial hypercholesterolemia and dyslipidemias basic management infrastructure in Pakistan: a cross-sectional study.
巴基斯坦家族性高胆固醇血症和血脂异常基本管理基础设施的映射:一项横断面研究。
Lancet Reg Health Southeast Asia. 2023 Feb 20;12:100163. doi: 10.1016/j.lansea.2023.100163. eCollection 2023 May.
4
Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.脂蛋白(a)检测的当代模式及相关临床护理与结果。
Am J Prev Cardiol. 2023 Mar 1;14:100478. doi: 10.1016/j.ajpc.2023.100478. eCollection 2023 Jun.
5
Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses.脂蛋白(a)检测的趋势和后果:横断面和纵向健康保险索赔数据库分析。
Atherosclerosis. 2023 Feb;367:24-33. doi: 10.1016/j.atherosclerosis.2023.01.014. Epub 2023 Jan 20.
6
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.脂蛋白(a)水平在已确诊动脉粥样硬化性心血管疾病的全球人群中的水平。
Open Heart. 2022 Oct;9(2). doi: 10.1136/openhrt-2022-002060.
7
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week.遗传背景、脂蛋白(a)与心血管风险阈值:JACC 本周综述主题。
J Am Coll Cardiol. 2022 Aug 30;80(9):934-946. doi: 10.1016/j.jacc.2022.06.019.
8
Lipoprotein(a) testing in clinical practice: real-life data from a large healthcare provider.临床实践中的脂蛋白(a)检测:来自大型医疗服务机构的真实数据。
Eur J Prev Cardiol. 2022 Oct 20;29(14):e331-e333. doi: 10.1093/eurjpc/zwac124.
9
Non-genetic influences on lipoprotein(a) concentrations.脂蛋白(a)浓度的非遗传影响。
Atherosclerosis. 2022 May;349:53-62. doi: 10.1016/j.atherosclerosis.2022.04.006.
10
Lipoprotein(a) and ethnicities.脂蛋白(a)与种族。
Atherosclerosis. 2022 May;349:42-52. doi: 10.1016/j.atherosclerosis.2022.04.005.